Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 16/20 | 0.55 |
| ▸ | MAOB | P27338 | 12/20 | 0.55 |
| ▸ | MAOA | P21397 | 9/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667830 | 1.00 | KCNH2 (0.56) | KCNH2KDM1AMAOBMAOARAB9A | |
| SCHEMBL1667828 | 1.00 | KCNH2 (0.56) | KCNH2KDM1AMAOBMAOARAB9A | |
| Hydrochloric Acid SCHEMBL13277807 | 0.99 | KCNH2 (0.55) | KCNH2KDM1AMAOBMAOARAB9A | |
| Hydrochloric Acid SCHEMBL13277806 | 0.99 | KCNH2 (0.55) | KCNH2KDM1AMAOBMAOARAB9A | |
| SCHEMBL11903562 | 0.90 | KDM1A (0.59) | KCNH2KDM1AMAOBMAOARAB9A | |
| SCHEMBL11903561 | 0.90 | KDM1A (0.59) | KCNH2KDM1AMAOBMAOARAB9A | |
| SCHEMBL1667796 | 0.88 | KDM1A (0.54) | KCNH2KDM1AMAOBMAOARAB9A | |
| SCHEMBL1667652 | 0.87 | KCNH2 (0.59) | KCNH2KDM1AMAOBMAOA | |
| SCHEMBL1667651 | 0.87 | KCNH2 (0.59) | KCNH2KDM1AMAOBMAOA | |
| SCHEMBL13453250 | 0.87 | KCNH2 (0.59) | KCNH2KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946296-B2 | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use | ORYZON GENOMICS S.A. (ES) | 2015-02-03 | — | — | US | disclosed |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | CBR1, CNR1, CBR3 | KCNH2 1511/4885KDM1A 877/4885MAOB 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.